Melanoma is one of the serious types of skin cancers that develops from pigment-containing cells called as melanocytes. Melanomas typically occur in the skin, but may rarely occur in the mouth, intestines, or eye. In women, they most commonly occur on the legs, while in men they are most common on the back. Moles, brown spots and growths on the skin are found to be the symptoms associated with the disease. When it spreads to other places in body, it's called metastatic, or advanced. Although in many cases metastatic melanoma can’t be cured, treatments and support can help people live longer and better. Doctors have therapies that have greatly increased survival rates. And researchers are working to find new medications that can do even more.
This report contains market size and forecasts of Metastatic Melanoma Diagnostic in Global, including the following market information:
Global Metastatic Melanoma Diagnostic Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Metastatic Melanoma Diagnostic market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
BRAF Mutation Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Metastatic Melanoma Diagnostic include Myriad Genetics, Abbott Laboratories, Foundation Medicine, Pathway Genomics Corporation, Cancer Genetics, Castle Biosciences, NeoGenomics, Dermtech and Sysmex Inostics. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Metastatic Melanoma Diagnostic companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Metastatic Melanoma Diagnostic Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Metastatic Melanoma Diagnostic Market Segment Percentages, by Type, 2021 (%)
BRAF Mutation
Circulating Tumor Cells (CTCs)
Immunohistochemistry
Others
Global Metastatic Melanoma Diagnostic Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Metastatic Melanoma Diagnostic Market Segment Percentages, by Application, 2021 (%)
Pathology Laboratories
Hospitals
Cancer Research Centres
Others
Global Metastatic Melanoma Diagnostic Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Metastatic Melanoma Diagnostic Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Metastatic Melanoma Diagnostic revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Metastatic Melanoma Diagnostic revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Myriad Genetics
Abbott Laboratories
Foundation Medicine
Pathway Genomics Corporation
Cancer Genetics
Castle Biosciences
NeoGenomics
Dermtech
Sysmex Inostics